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Abstract
Background: Population-based electronic immunization registries create the possibility of using registry
data to conduct vaccine effectiveness studies which could have methodological advantages over traditional
observational studies. For study validity, the base population would have to be clearly defined and the
immunization status of members of the population accurately recorded in the registry. We evaluated a
city-wide immunization registry, focusing on its potential as a tool to study pertussis vaccine effectiveness,
especially in adolescents.
Methods: We conducted two evaluations – one in sites that were active registry participants and one in
sites that had implemented an electronic medical record with plans for future direct data transfer to the
registry – of the ability to match patients' medical records to registry records and the accuracy of
immunization records in the registry. For each site, records from current pediatric patients were chosen
randomly. Data regarding pertussis-related immunizations, clinic usage, and demographic and identifying
information were recorded; for 11–17-year-old subjects, information on MMR, hepatitis B, and varicella
immunizations was also collected. Records were then matched, when possible, to registry records. For
records with a registry match, immunization data were compared.
Results: Among 350 subjects from sites that were current registry users, 307 (87.7%) matched a registry
record. Discrepancies in pertussis-related data were common for up-to-date status (22.6%), number of
immunizations (34.7%), dates (10.2%), and formulation (34.4%). Among 442 subjects from sites that
planned direct electronic transfer of immunization data to the registry, 393 (88.9%) would have matched
a registry record; discrepancies occurred frequently in number of immunizations (11.9%), formulation
(29.1%), manufacturer (94.4%), and lot number (95.1%.) Inability to match and immunization discrepancies
were both more common in subjects who were older at their first visit to the provider site. For 11–17-
year-old subjects, discrepancies were also common for MMR, hepatitis B, and varicella vaccination data.
Conclusion: Provider records frequently could not be matched to registry records or had discrepancies
in key immunization data. These issues were more common for older children and were present even with
electronic data transfer. These results highlight general challenges that may face investigators wishing to
use registry-based immunization data for vaccine effectiveness studies, especially in adolescents.
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Background
Population-based electronic immunization registries have
the potential to reduce fragmentation of immunization
records and to enhance immunization delivery [1,2].
Recently, much progress has been made in implementing
registries at state, city, and regional levels [3,4]. The advent
of electronic registries creates the possibility of using reg-
istry data to conduct vaccine effectiveness studies [5]. Reg-
istry-based studies could have several methodological
advantages over traditional observational studies of vac-
cine effectiveness. First, the availability of individual-level
immunization information for each person, or at least
each child, in a population could allow large cohort stud-
ies to be conducted efficiently. This efficiency could
reduce reliance on case control studies, which may be
more prone to bias than cohort studies. Second, the ease
of collecting immunization data from a registry also
means that cohort studies could be conducted even in
populations with low incidence of the vaccine-preventa-
ble disease under study. Studies conducted in outbreak
settings may tend to underestimate vaccine effectiveness
[6], so vaccine effectiveness studies conducted outside of
outbreak situations are valuable in estimating the typical
effectiveness of a vaccine. Third, the availability of com-
plete and accurate information on the immunization sta-
tus of residents of a registry's catchment area could also
help avoid bias due to differential determination of
immunization status among ill and well persons [7].
However, for a registry-based study to be valid, the base
population must be clearly defined and the immuniza-
tion status of the members of the population must be
accurately recorded in the registry.
We conducted an evaluation of the Boston Immunization
Information System, hereafter termed "the registry,"
focusing on its potential usefulness as a tool to study per-
tussis vaccine effectiveness, especially in adolescents. The
registry has been operating since 1992. It was developed
by the Boston Public Health Commission to support
efforts to achieve and maintain high immunization cover-
age for infants and young children [8]. Boston has been
remarkably successful in meeting this goal; its immuniza-
tion coverage is among the highest of any large city in the
nation [9]. Children are enrolled in the registry by their
primary care providers, and provider immunization
records are transferred regularly from participating pri-
mary care sites using customized software provided to
each participating site. Sites have varied greatly in their
technical capacity; early in the registry's history, some sites
used manual data entry, which in some cases required
double data entry, while others used electronic methods.
At the time of this study, all sites used some form of elec-
tronic data entry and few required double data entry.
Computing resources have improved over time, though,
and, at the time of our evaluation, most sites were sending
data directly to the registry from their own electronic
records [8].
In many vaccine effectiveness studies, cases of disease are
identified when patients with the vaccine-preventable dis-
ease are reported to a health department. In a registry-
based vaccine effectiveness study, these cases would then
be matched to registry vaccination records. Both the abil-
ity to match patients to registry records and the accuracy
of those records would be important to the validity of the
registry-based study. To simulate this process, we selected
patients from pediatric primary care sites that participate
in the registry and attempted to match these patients to
registry records. Then, for children whose records could be
matched, we evaluated whether discrepancies existed
between the provider immunization record and the regis-
try immunization record. We examined the kinds of dis-
crepancies that occurred, to distinguish insignificant
discrepancies from major ones that might limit the scope
or accuracy of a vaccine effectiveness study. To enhance
accuracy and efficiency, many registries and health care
providers are moving toward direct transfer of immuniza-
tion data to immunization registries from electronic med-
ical records (EMRs). Therefore, we examined separately
the expected completeness and accuracy of immunization
data transmitted to the registry from providers using an
EMR. Our assessment revealed several issues that could
seriously limit the reliability of vaccine effectiveness stud-
ies using the registry. We believe that some of these prob-
lems may, to varying degrees, apply to other registries and
have therefore summarized our findings and considered
their general implications for investigators conducting
registry-based vaccine effectiveness studies.
Methods
The registry serves 23 health care sites that provide the
great majority of the pediatric primary care for Boston, an
urban setting with a 2000 population of about 116,000
children < 18 years old [10]. Only one practice site is pri-
vate; all others are either in community health centers or
in academic medical centers. This study consisted of two
separate evaluations of the ability to match patients' med-
ical records to registry records and the accuracy of immu-
nization records in the registry. The first evaluation
focused on pediatric primary care sites that were active
registry participants, appraising the registry's current per-
formance. This evaluation thus reflects the cumulative
impact of all methods used for immunization data trans-
fer to the registry over the history of the registry, through
the time of the evaluation. The second evaluation focused
on sites that had implemented a comprehensive EMR
within 2–3 years before the evaluation. This second eval-
uation thus appraises the expected registry performance
with direct transfer of immunization data from the EMR
to the registry. The study was approved by institutional
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review boards serving all participating primary care sites,
the Boston Public Health Commission, and the Boston
University Schools of Public Health and Medicine. Only
Boston Public Health Commission registry managers had
access to individual registry records; registry data provided
to Boston University investigators were either aggregated
or de-identified.
Collection of data from primary care providers
Pediatric primary care sites were identified by registry
managers as 1) current registry users with good overall
data integrity and completeness or 2) future direct-EMR-
transfer users – former registry users that had temporarily
stopped transferring data to the registry to allow imple-
mentation of the EMR with direct data transfer. All sites
were invited to participate in the data quality review. Data
were collected from August 2004 through February 2005
from sites that enrolled. For each primary care site, a ran-
dom sample of pediatric records from current patients
aged 0–10 and 11–17 years was chosen for review from
the site's list of patients. For sites that reported serving <
5000 pediatric patients, 25 charts were chosen within
each age group; for larger sites, 50 records were chosen
within each age group. All components of each subject's
medical record, including all volumes of paper records
and all electronic records, were reviewed. For each subject,
information on all immunizations containing diphtheria
and tetanus toxoids was recorded; both those with and
without pertussis antigens were included. We refer to
these immunizations as "pertussis-related" hereafter. Data
included the immunization date, formulation (DTwP,
DTaP, DT, or Td; Tdap had not been introduced at the
time of the study), manufacturer, and lot number. Addi-
tional data for each subject included 1) identifying infor-
mation that might assist in matching records to the
registry, including name, sex, date of birth, address, and
mother's name; 2) dates of the patient's first visit to and
first immunization at the primary care site; 3) for 11–17-
year-olds, dates of MMR, hepatitis B, and varicella immu-
nizations. When immunization data were recorded more
than once in a subject's medical record, the data entered
closest to the immunization date were considered to be
the most accurate.
Matching subjects to registry records
For primary care sites that were current registry users, sub-
jects were matched to registry records by registry manag-
ers. A match was defined as occurring when a subject's
provider record matched exactly one registry record with
definite correspondence of at least name, sex, and date of
birth. The spelling of names was not required to be iden-
tical. When more than one registry record existed for a
given name, sex, and date of birth, other identifying data
including immunization dates could be used to determine
whether there was a match. For primary care sites that
were future direct-EMR-transfer users, identifying data in
the EMR would be expected to be identical to directly
transferred registry data. Therefore, failure to match would
be expected to occur only if a patient's paper medical
record had not been updated into an EMR during the
implementation of the EMR system. Therefore, for sub-
jects from these sites, failure to match was considered to
occur only when a subject did not have an EMR.
Evaluation of immunization discrepancies between 
provider and registry records
For subjects from sites that were current registry users and
who matched a registry record, registry managers evalu-
ated whether discrepancies in immunization data existed
between the provider record and the registry record. For
each pertussis-related immunization, date discrepancies
were categorized as 1–29 days difference, 30–364 days
difference, or t 1 year difference; formulation discrepan-
cies were noted; and, for provider records with manufac-
turer and lot number information, any discrepancies in
these fields were noted. Also, registry managers noted
whether any discrepancies would have affected overall
agreement between the provider record and the registry
record as to whether the subject was currently up-to-date
for pertussis-related immunization. For 11–17-year-old
subjects, provider records of MMR, hepatitis B, and vari-
cella immunization dates were compared to registry
records using the same methods. To evaluate the sensitiv-
ity of the registry managers' evaluation of immunization
discrepancies, artificial discrepancies were created in 10%
of provider records and the detection of these discrepan-
cies was tracked.
For subjects from primary care sites that were future
direct-EMR-transfer users, immunization data in the EMR
was considered to represent the data that would exist in
the registry; the current EMR served as a proxy for the reg-
istry. Therefore, an immunization discrepancy was con-
sidered to have occurred when data in the EMR differed
from data in the entire medical record, including all orig-
inal volumes of the original paper record.
Statistical analysis
We calculated frequencies of record matching and, among
matched records, frequencies of discrepancies in immuni-
zation information for current user sites as a group, for
future direct-EMR-transfer sites as a group, and for each
site individually. We categorized both current age and age
at first visit to the provider site into two categories – 0–10-
years-old and 11–17-years-old. We then used the chi-
square statistic to test differences in matching frequency.
We used logistic regression to examine the independent
contributions of current age, age at first visit to the pro-
vider site, and sex to 1) ability to match a registry record
and 2) among matched records, discrepancy in whether
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the subject was up-to-date for pertussis-related immuniza-
tion, constructing separate models for subjects from cur-
rent user sites and from future direct-EMR-transfer sites.
We analyzed the data with Excel 2003 and SAS version 9.1
(SAS Institute, Inc., Cary, NC).
Results
Population
Data were collected at 6 of the 8 pediatric primary care
sites that were current registry users and at 7 of the 8 sites
that were future direct-EMR-transfer users; the other 7 sites
did not fit either category. Of 350 medical records selected
at the 6 current user sites, 100% were available for review
and abstraction of the demographic, clinical, and immu-
nization-related data described above in the section on
collection of data from primary care providers. Of 450
medical records selected at the 7 future direct-EMR-trans-
fer sites, 442 (98.2%) were available.
Matching
Among the 350 subjects from sites that were current regis-
try users, 307 (87.7%) were definitively matched to a reg-
istry record, with a range among sites from 82.0% to
100%. Of these matched records, 300 (98.4%) were
matched using only name, sex, date of birth, and, in some
cases, address information; other identifying information
was rarely needed. Among the 442 subjects from future
direct-EMR-transfer sites, 393 (88.9%) would have
matched a registry record once direct EMR transfer started,
with the range among sites again 82.0% to 100%. An EMR
did not exist for the remaining 11.1% of subjects from
direct-EMR-transfer sites. These subjects had only a paper
medical record and therefore would not have been repre-
sented in a registry populated by direct EMR transfer
despite being considered current patients by the primary
care site from which they were selected. Subjects who were
11–17 years old when they first visited their primary care
site were less likely to match a registry record than subjects
who were 0–10 years old at their first visit. This was true
both at sites that were current registry users and future
direct-EMR-transfer users (Table 1). In logistic regression
models, age at first visit to the primary care site was the
only statistically significant predictor of matching a regis-
try record for both current user sites (adjusted odds ratio
(aOR) for 0–10-year-old age group = 10.8, p = 0.0001)
and future direct-EMR-transfer sites (aOR for 0–10-year-
old age group = 4.0, p = 0.0005).
Pertussis immunization discrepancies
From primary care sites that were current registry users,
288 matched records contained at least one immuniza-
tion and so could be analyzed for accuracy of immuniza-
tion data. In all, these records included 1410 pertussis-
related immunizations (based on provider records, 522
DTwP, 464 DTaP, 135 DT or Td, and 289 with the formu-
lation not recorded.) From future direct-EMR-transfer
users, 377 matched records with 1848 pertussis-related
immunizations were analyzed (based on provider
records, 623 DTwP, 712 DTaP, 197 DT or Td, and 316
with the formulation not recorded). Table 2 presents data
regarding discrepancies in all aspects of pertussis-related
immunization. For subjects from current registry user
sites, discrepancies were common in up-to-date status
(22.6% of series had a discrepancy), number of pertussis-
related immunizations received (34.7% of series had a
discrepancy), dates (23.6% of series and 10.2% of immu-
nizations had a discrepancy), and formulation (34.4% of
immunizations had a discrepancy), with great variation
between primary care sites. Manufacturer and lot number
were rarely recorded in provider records and, when
recorded, were all discrepant in the registry. For subjects
from future direct-EMR-transfer sites, discrepancies were
less common but still frequently present, especially for
number of pertussis immunizations received (11.9% of
series had a discrepancy), formulation (29.1% of immu-
nizations had a discrepancy), manufacturer (94.4% of
immunizations with manufacturer recorded in the pro-
vider record were missing manufacturer information in
Table 1: Ability to match primary care provider records to registry records by current age and age at first visit to the primary care 
site.
Current Registry Users Future-Direct-EMR Users
Number with registry 
match/total
Percent with registry 
match
P-value* Number with registry 
match/total
Percent with registry 
match
P-value*
Subject age group at 
time of review
0–10 years 152/173 87.9 0.94 201/216 93.1 0.0067
11–17 years 155/177 87.6 192/226 85.0
Age at first visit to 
primary care site
0–10 years 274/301 91.0 < 0.0001 343/374 91.7 < 0.001
11–17 years 25/40 62.5 36/52 69.2
* Chi-square test statistic
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the registry), and lot number (95.1% of immunizations
with lot number recorded in the provider record were
missing lot number information in the registry.) Discrep-
ancies were generally more common for 11–17-year-olds
than for 0–10 year-olds (Table 3.) Logistic regression
modeling showed that age at first visit to the primary care
site was the only significant predictor of a discrepancy in
up-to-date status for subjects from current user sites
(adjusted odds ratio (aOR) for 0–10-year-old age group =
2.4, p = 0.03). Because very few discrepancies in up-to-
date status occurred for direct-EMR-transfer sites, logistic
models for this outcome could not be constructed for sub-
jects from these sites.
Discrepancies for adolescents in other immunizations
Table 4 presents data on discrepancies between provider
records and registry records of MMR, hepatitis B, and vari-
cella immunizations of 11–17-year-olds, based on 143
Table 2: Discrepancies in pertussis-related immunization data between provider records and the immunization registry.
Current registry user sites Future direct-EMR-transfer sites
n % with discrepancy Range among provider sites n % with discrepancy Range among provider sites
Discrepancies in pertussis-
related immunization series
Discrepancy in whether 
subject is up-to-date for 
pertussis-related 
immunizations
288 22.6 12.4–45.7 377 4.0 0–18.6
Discrepancy in number of 
pertussis-related 
immunizations received 
by subject
288 34.7 19.8–60.1 377 11.9 5.0–30.2
Any present in 
provider record but 
not in registry
288 27.8 11.9–60.9 377 0.3 0–1.2
Any present in registry 
but not in provider 
record
288 9.7 4.8–17.5 377 0.3 0–1.2
Discrepancy in date of 
any pertussis-related 
immunization in series
288 23.6 13.2–35.0 377 18.0 10.9–36.9
Discrepancy in 
formulation of any 
pertussis-related 
immunization in series
288 11.1 0–24.4 377 5.3 0–23.3
Discrepancies in pertussis-
related immunizations
Date discrepancy 1410 10.2 6.1–15.8 1848 8.0 5.5–17.0
Discrepancy of 1–29 
days
1410 9.0 4.5–15.3 1848 6.6 3.0–16.5
Discrepancy of 1–11 
months
1410 0.9 0–1.5 1848 0.8 0–2.0
Discrepancy of t 1 
year
1410 0.4 0–0.5 1848 0.5 0–1.5
Discrepancy in 
formulation
34.4 11.8–50.1 29.1 17.6–36.9
Discrepancy in 
whether pertussis-
related immunization 
contained pertussis 
vaccine (vs diphtheria-
tetanus only)
1410 0.6 0–2.0 0.4 0–1.2
Discrepancy in 
manufacturer, among 
those with manufacturer 
noted in provider record
468 100 NA 645 94.4 76.2–100
Discrepancy in lot 
number, among those 
with lot number noted in 
provider record)
539 100 NA 693 95.1 37.5–100
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Table 3: Discrepancies in pertussis-related immunization data between provider records and the immunization registry by age group.
% of subjects with discrepancy
Current registry user sites
% of subjects with discrepancy
Future direct-EMR-transfer sites
0–10 years old 11–17 years old 0–10 years old 11–17 years old
Discrepancies in pertussis-related immunization series
Discrepancy in whether subject is up-to-date for pertussis-related 
immunizations
26.1 19.2 3.1 5
Discrepancy in number of pertussis-related immunizations received by 
subject
30.3 37.7 7.2 17
Any present in provider record but not in registry 23.2 32.2 0 0.6
Any present in registry but not in provider record 5.6 13.7 0 0.6
Discrepancy in date of any pertussis-related immunization in series 16.9 30.1 15.9 20.3
Discrepancy in formulation of any pertussis-related immunization in 
series
12.0 10.3 4.1 6.6
Discrepancies in pertussis-related immunizations
Date discrepancy 4.9 14.3 5.5 10.2
Discrepancy of 1–29 days 3.8 13.1 4.4 8.5
Discrepancy of 1–11 months 1 0.8 0.8 0.8
Discrepancy of t 1 year 0.2 0.5 0.2 0.8
Discrepancy in formulation 28.3 39.1 21.4 35.7
Discrepancy in whether pertussis-related immunization contained 
pertussis vaccine (vs diphtheria-tetanus only)
0 1.1 0 0.8
Discrepancy in manufacturer, among those with manufacturer noted in 
provider record
100 100 99.8 86.1
Discrepancy in lot number, among those with lot number noted in 
provider record)
100 100 99.8 89.0
Table 4: Discrepancies for 11–17-year-olds in MMR, hepatitis B, and varicella immunization data in provider records and the 
immunization registry.
Current registry user sites
N = 6 sites, 143 matched records
Future direct-EMR-transfer sites
N = 7 sites, 180 matched records
% with
discrepancy
Range among provider sites % with
discrepancy
Range among provider sites
MMR
Discrepancy in whether subject is up-to-date for MMR 
immunization
19.6 9.5–43.5 14.4 5.3–36.4
Discrepancy in number of MMR immunizations 
received by subject
18.2 9.5–43.5 11.1 0–31.8
Discrepancy in date of any MMR immunization in series 22.4 5.3–33.3 16.1 7.5–38.1
Hepatitis B
Discrepancy in whether subject is up-to-date for 
hepatitis B immunization
29.4 9.5–82.6 13.9 5.3–31.8
Discrepancy in number of hepatitis B immunizations 
received by subject
27.3 10.0–78.3 12.8 4.8–22.7
Discrepancy in date of any hepatitis B immunization in 
series
16.8 10.5–23.8 16.1 5.3–29.4
Varicella
Discrepancy in whether subject is up-to-date for 
varicella immunization
69.2 23.8–100 63.9 57.5–82.4
Discrepancy in number of varicella immunizations 
received by subject*
30.4 20.0–80.0 7.6 0–20.0
Discrepancy in date of any varicella immunization in 
series*
3.6 0–10.0 2.9 0–20.0
*Excludes provider records with documentation of varicella disease.
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matched records with immunization data from this age
group from current registry user sites and 180 from future
direct-EMR-transfer sites. As for pertussis-related immuni-
zations, discrepancies in up-to-date status, number of
immunizations received, and dates were common overall
and were more common in records from current registry
user sites than from future direct-EMR-transfer sites. Vari-
cella up-to-date status was especially likely to be discrep-
ant.
Sensitivity of registry review for discrepancies
Among 35 artificial discrepancies introduced into data
abstracted from current registry user sites, 29 occurred in
matched records. Registry managers detected 28 of those,
for a sensitivity of 97%.
Discussion
For several measures critical to vaccine effectiveness stud-
ies, this study showed that Boston's immunization regis-
try would have significant shortcomings as a source of
immunization data. Problems, discussed in more detail
below, included inability to match subjects to registry
records and incomplete and inaccurate immunization
data. This registry is of one of the nation's oldest, so its
data may reflect the cumulative impact of both popula-
tion mobility and historical methods of data capture that
are not manifest to the same degree in newer registries.
This interpretation is supported by our finding that data
for adolescents were generally less reliable than for
younger children. Also, reflecting the delivery of pediatric
care in Boston, almost all sites participating in this registry
are community health or academic medical centers.
Nationwide, however, most immunizations are delivered
in the private practice setting, with processes and docu-
mentation that may differ from those used in the Boston
sites. We doubt that the problems revealed in our study
are unique to this registry, however. Previous studies of
registries focusing on vaccination delivery and coverage,
rather than on vaccine effectiveness, have shown varying
but suboptimal completeness and accuracy [11-15].
Although the problems we found may (or may not) be
particularly severe in this registry, our findings highlight
general challenges that may face investigators wishing to
use registry-based immunization data for vaccine effec-
tiveness studies.
Matching persons identified with cases of the vaccine-pre-
ventable disease under study to their registry immuniza-
tion records is likely to be a first step in many registry-
based vaccine effectiveness studies. In this registry, match-
ing was incomplete in all age groups and was particularly
problematic in children who were in the 11–17-year-old
age group at their first visit to their primary care provider.
We do not know whether these children moved to Boston
from another location or transferred from one provider to
another within the city, but the finding provides a cau-
tionary note for the use of registry data in studies of ado-
lescents. It might be tempting to include persons with
disease in a vaccine effectiveness study regardless of
whether they match a registry record, since their immuni-
zation records are likely to be available from other
sources. However, doing so could bias the estimate of vac-
cine effectiveness, if the vaccination status of persons who
match a registry record is systematically different from
that of persons who do not match. For example, persons
with a matching registry record might be, on average,
more completely vaccinated than persons without a
matching registry record. If so, then a study including dis-
eased persons who do not match a registry record would
upwardly bias vaccine effectiveness estimates, because
these cases would be less likely to be completely vacci-
nated than the population represented by the registry
independent of any protective effect of the vaccine.
We suspect that two main factors, both with implications
for vaccine effectiveness studies, account for the lower reg-
istry matching rates of older children. First, the registry
was launched in 1992, meaning that the oldest patients
enrolled during infancy would have been 13 years old
during our evaluation; patients older than 13 were neces-
sarily enrolled at older ages with retrospective entry of
their historical immunization data. Vaccine effectiveness
studies in adolescents are of current interest, as several
new vaccines have recently been recommended for this
age group [16-18]. If subjects in a registry-based study are
older than the registry, investigators will need to consider
how historical data were handled. Second, the US popula-
tion has high rates of moving between states or regions
[19]; even registries that automatically enroll children at
birth could be prone to incomplete matching of children
who move into the registry catchment area later in life.
Direct transfer of data from EMRs into the registry might
be expected to solve the problem of incomplete matching,
at least for children served by providers using EMRs. Inter-
estingly, though, using EMR data as a proxy for registry
data and comparing these data to the entire medical
record, we found that similar rates of failure to match –
slightly lower in 0–10-year-olds and slightly higher in 11–
17-year-olds – would be expected for children from sites
using an EMR. This phenomenon occurred because most
provider sites did not create an EMR for all of their existing
patients during implementation of the EMR system; a reg-
istry record would only be generated through direct data
transfer for patients with an EMR.
Patterns of immunization data discrepancy for children
who did match a registry record also have important
implications for vaccine effectiveness studies. Most dis-
crepancies in the number of pertussis-related immuniza-
tion were due to immunizations that were recorded in the
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provider record but were absent from the registry (Table
2), implying that the registry record, not the provider
record, was incomplete. We also found that the data on
vaccine formulation, manufacturer, and lot number were
often either absent from the provider record or, when
present, discrepant in the registry. These types of discrep-
ancies have minimal consequences for achieving the reg-
istry's primary goal, supporting efforts to achieve and
maintain high immunization coverage among young chil-
dren, aside from time lost in tracking children who appear
incorrectly to have immunization delay. For vaccine effec-
tiveness studies, however, these discrepancies could have
important implications. The importance of using compa-
rable methods to determine vaccination status of diseased
and non-diseased subjects has been emphasized previ-
ously [7]; for registry-based studies, this principle implies
that, if the registry is the sole source of vaccination infor-
mation for non-cases or the population as a whole, then
it should be the sole source for cases also. Even if immu-
nization data for all study subjects is obtained from a reg-
istry, however, to the extent that some immunizations are
missing from the registry (and that the pattern of missing
immunizations is not related to disease status), vaccine
effectiveness estimates will be biased toward the null.
Immunization data that are captured and transmitted to a
registry from EMRs or by other electronic means should
be more accurate than data transmitted by other methods
[20,21], but our data show that, beyond the errors that
can occur during actual use of electronic medical records,
much information can be lost from paper records during
the implementation of the electronic system. Investigators
should therefore consider the impact of all the methods of
data entry used over a registry's history for studies in
which data for any immunizations under study would
have been entered using past methods.
Before relying on registry data for a registry-based vaccine
effectiveness study, therefore, we suggest that it would be
prudent to conduct an evaluation of the registry's popula-
tion coverage and data quality. We recognize, however,
that conducting such an evaluation may in itself be chal-
lenging. Registries are intentionally and appropriately
designed with a high level of confidentiality for participat-
ing patients and provider sites and so may be prohibited
from releasing to investigators the individual-level data
needed to conduct such an evaluation [1,2,22,23]. In our
case, compliance with registry confidentiality policies
meant that we needed to develop a somewhat cumber-
some method for reviewing data abstracted from provider
records that was labor-intensive for registry managers.
However, a registry-based vaccine effectiveness study con-
ducted without this evaluation would almost certainly
have produced misleading results.
Conclusion
In summary, our evaluation revealed limitations with reg-
istry data – frequent inability to match provider records to
registry records as well as frequent discrepancies in key
immunization data – that have implications both for
defining study populations and for conducting data col-
lection for vaccine effectiveness studies. These issues were
more common for older children and were present even
with electronic data transfer. Registry characteristics
required to support immunization delivery do not neces-
sarily translate into complete and accurate vaccination
information for the population as a whole. These results
highlight general challenges that may face investigators
wishing to use registry-based immunization data for vac-
cine effectiveness studies, especially in adolescents. The
frequency of incomplete and inaccurate information will
certainly differ between registries, but we believe the qual-
itative lessons learned from this evaluation are likely to be
applicable to other registries.
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